Seeking Alpha HealthcareOriginal article
DiaMedica anticipates ReMEDy2 interim analysis in Q1 2027 as enrollment surpasses 85% of 200-patient trigger
Data ReadoutReMEDy2Positive
AI Analysis
Summary
DiaMedica reports ReMEDy2 trial enrollment has surpassed 85% of the 200-patient trigger, with interim analysis anticipated in Q1 2027.
Clinical Trial Data
Patients
200
Outcome Details
Interim analysis anticipated
Importance:5/10
Sentiment:
0.30
clinical_trialinterim_analysisenrollment_progress
Related Companies
Read the original article
Published by Seeking Alpha Healthcare on August 11, 2026 3:48 PM